Preprint Case Report Version 1 Preserved in Portico This version is not peer-reviewed

Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)

Version 1 : Received: 28 April 2021 / Approved: 29 April 2021 / Online: 29 April 2021 (15:38:30 CEST)

How to cite: Gurruchaga Sotés, I.; Santander Lobera, C. Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC). Preprints 2021, 2021040780 (doi: 10.20944/preprints202104.0780.v1). Gurruchaga Sotés, I.; Santander Lobera, C. Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC). Preprints 2021, 2021040780 (doi: 10.20944/preprints202104.0780.v1).

Abstract

In clinical guidelines, such as National Comprehensive Cancer Network guidelines, it is embodied as first therapeutic option the combination of erlotinib and bevacizumab, based on a small clinical trial which included patients with HLRCC. With this case report we bring out another treatment option, not described before, with extraordinary results based on the combination of a check-point inhibitor and a tyrosine-kinase inhibitor, based on theoretical tumor immunogenic environment.

Keywords

Hereditary Leyomiomatosis and Renal Cell Cancer; Pembrolizumab; Axitinib

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.